Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Our Vision
To develop and launch the first targeted cellular therapies for patients with autoimmune diseases. When we succeed, we will be:
- Champions to patients
- Valued partners to physicians
- Preferred collaborators to scientists and partners
- Family to each other
- Value-added providers to payors
- Trusted, transparent, and reliably providing a fair return to our investors